DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy

• Status: Completed
• Trial end date: 2005-06-01

Summary

The purpose of this study is to evaluate whether a therapy with an all once daily regimen of stavudine extended release (d4T XR), lamivudine (3TC), and efavirenz (EFV) leads to improved outcomes, as measured by viral load, CD4 counts, adherence, safety, and tolerability.

• Phase: Phase 4

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Efavirenz; Lamivudine; Stavudine